- AI in drug discovery, utilizing machine learning, deep learning, and data-driven modeling, is becoming a critical enabler in transforming the pharmaceutical R&D landscape across North America by improving the efficiency and accuracy of early-stage drug development processes such as target identification, hit discovery, and molecule optimization
- The escalating demand for AI in drug discovery is primarily fueled by increasing healthcare R&D investments, growing prevalence of chronic and rare diseases, and a rising need to reduce the time and cost associated with traditional drug development cycles
- U.S. dominated the North America artificial intelligence (AI) in drug discovery market with the largest revenue share of 48.7% in 2024, characterized by advanced healthcare infrastructure, early adoption of AI technologies, and strong collaborations between pharmaceutical companies and AI-focused tech firms
- Canada is expected to be the fastest growing country in the North America artificial intelligence (AI) in drug discovery market during the forecast period, driven by increasing government support for AI in healthcare, a growing biotechnology sector, and rising collaborations between Canadian research institutions and pharmaceutical companies to apply AI in drug development
- Small Molecule segment dominated the Nor North America artificial intelligence (AI) in drug discovery market with a market share of 64% in 2024, driven by its ease of modeling, scalability in screening, and widespread use in targeted therapies
